

ESM 5. Supplementary Table 4. Heterogeneity assessment across studies for all outcomes. Heterogeneity statistic, I<sup>2</sup> and tau<sup>2</sup>.

Comparison	Chi <sup>2</sup>	df	p-value	I <sup>2</sup>	tau <sup>2</sup>
<b>Efficacy endpoint (stroke, stroke/SE, stroke/TIA/SE)</b>					
D - V	105.44	38	<0.001	64.0%	0.021
R - V	56.08	22	<0.001	60.8%	0.019
A - V	88.29	13	<0.001	85.3%	0.064
D - R	18.79	19	0.470	0.0%	0.000
D - A	31.29	9	<0.001	71.2%	0.042
R - A	30.98	10	0.001	67.7%	0.038
<b>Major bleeding</b>					
D - V	396.16	41	<0.001	89.7%	0.074
R - V	119.37	21	<0.001	82.4%	0.030
A - V	54.36	18	<0.001	66.9%	0.017
D - R	16.32	21	0.752	0.0%	0.000
D - A	70.12	16	<0.001	77.2%	0.060
R - A	81.47	16	<0.001	80.4%	0.061
<b>Intracranial bleeding</b>					
D - V	49.68	38	0.097	23.5%	0.016
R - V	24.43	17	0.108	30.4%	0.028
A - V	13.90	11	0.239	20.8%	0.021
D - R	35.41	16	0.003	54.8%	0.120
D - A	11.58	7	0.115	39.5%	0.086
R - A	5.08	8	0.749	0.0%	0.000
<b>Gastrointestinal bleeding</b>					
D - V	123.74	27	<0.001	78.2%	0.041
R - V	30.22	11	0.001	63.6%	0.024
A - V	9.53	4	0.049	58.0%	0.018
D - R	18.72	12	0.095	35.9%	0.011
D - A	40.53	3	<0.001	92.6%	0.317
R - A	42.01	3	<0.001	92.9%	0.363

**Myocardial infarction**

<b>D - V</b>	55.56	17	<0.001	69.4%	0.059
<b>R - V</b>	8.58	5	0.127	41.7%	0.024
<b>A - V</b>	0.04	1	0.848	80.0%	0.000
<b>D - R</b>	5.46	5	0.362	28.5%	0.004

**Deaths**

<b>D - V</b>	231.93	15	<0.001	93.5%	0.128
<b>R - V</b>	76.59	5	<0.001	93.5%	0.105
<b>A - V</b>	89.33	2	<0.001	97.8%	0.377
<b>D - R</b>	13.10	7	0.070	46.5%	0.013
<b>D - A</b>	9.25	2	0.010	78.4%	0.084
<b>R - A</b>	15.38	2	<0.001	87.0%	0.089

---